Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

SOCS3 as a future target to treat metabolic disorders

Texto completo
Autor(es):
Pedroso, Joao A. B. [1] ; Ramos-Lobo, Angela M. [1] ; Donato, Jr., Jose [1]
Número total de Autores: 3
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Dept Physiol & Biophys, Inst Biomed Sci, Ave Prof Lineu Prestes, 1524, BR-05508000 Sao Paulo - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo de Revisão
Fonte: HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM; v. 18, n. 2, p. 127-136, JUN 2019.
Citações Web of Science: 3
Resumo

The suppressors of cytokine signaling (SOCS) are a group of eight proteins responsible for preventing excessive cytokine signaling. Among this protein family, SOCS3 has received special attention. SOCS3 expression is important to control certain allergy autoimmune diseases. Furthermore, SOCS3 expression is elevated in obesity and it is involved in the inhibition of leptin and insulin signaling, two important hormones involved in the control of energy metabolism. Therefore, increased SOCS3 expression in obese individuals is associated with several metabolic disorders, including reduced energy expenditure, increased food intake and adiposity, and insulin and leptin resistance. In addition, recent studies found that SOCS3 expression regulates energy and glucose homeostasis in several metabolic conditions, such as pregnancy, caloric restriction, and refeeding. Importantly, attenuation of SOCS3 expression in most cases improves leptin and insulin sensitivity, leading to beneficial metabolic effects. This review aims to discuss the role of SOCS3 in the control of blood glucose levels as well as in energy homeostasis. The development of pharmacological compounds to inhibit SOCS3 activity and/or expression may represent a promising therapeutic approach to treat type 2 diabetes mellitus, obesity, and other metabolic imbalances. (AU)

Processo FAPESP: 13/25032-2 - O papel do SOCS3 no controle da hiperfagia, reganho de peso corporal e gliconeogênese após um período de restrição alimentar
Beneficiário:João Alfredo Bolivar Pedroso
Linha de fomento: Bolsas no Brasil - Doutorado
Processo FAPESP: 17/02983-2 - Ação do hormônio do crescimento no sistema nervoso: relevância para as funções neurais e na doença
Beneficiário:Jose Donato Junior
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 14/11752-6 - Estudo das funções da leptina durante o período intrauterino e infância no camundongo
Beneficiário:Angela Maria Ramos Lobo
Linha de fomento: Bolsas no Brasil - Doutorado